Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases

Rheumatology

Volumn 43, Issue 2, 2004, Pages 229-233

  Zulian, F ^d,e   Corona, F ^a   Gerloni, V ^a   Falcini, F ^b   Buoncompagni, A ^c   Scarazatti, M ^a   Martini, G ^d   Zacchello, F ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e Department of Pediatrics   (Italy)

Author keywords

Iloprost; Ischaemic digits; Necrotizing vasculopathy; Paediatrics CTD

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ILOPROST; IMMUNOGLOBULIN; METHOTREXATE; WARFARIN;

ADOLESCENT; ANALGESIA; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CRITICAL ILLNESS; DEMOGRAPHY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FINGER; FINGER AMPUTATION; FINGER BLOOD FLOW; FINGER TIP INJURY; FOLLOW UP; GANGRENE; HEADACHE; HEALING; HUMAN; HYPOTENSION; INJECTION PAIN; IRRITABILITY; ISCHEMIA; LABORATORY TEST; MALE; MYALGIA; NAUSEA AND VOMITING; PAIN ASSESSMENT; POLYARTERITIS NODOSA; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SIDE EFFECT; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TISSUE NECROSIS; TREATMENT OUTCOME; VASODILATATION; WITHDRAWAL SYNDROME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CONNECTIVE TISSUE DISEASES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FINGERS; HUMANS; ILOPROST; INFANT; INFUSIONS, INTRAVENOUS; ISCHEMIA; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 1242342201     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg480     Document Type: Article

References (19)

1. Athreya BH. Vasculitis in children. Pediatr Clin North Am 1995;42:1239-61.
2. Cassidy JT, Petty RE. Systemic vasculitis. In: Cassidy JT, Petty RE, eds. Textbook of Pediatric Rheumatology, 4th edn. W.B. Saunders, 2001:564-604.
3. Dormandy JA. Use of prostacyclin analogue iloprost in the treatment of critical leg ischemia. Therapie 1991;46:319-22.
4. Fiessinger JN, Schäfer M. Trial of iloprost versus aspirin treatment for critical limb ischemia for thromboangiitis obliterans. Lancet 1990;335:555-7.
5. 2) analog in severe peripheral arterial disease (PAD). Adv Prost Thromb Leukot Res 1989;19:311-6.
6. Watson HR, Belcher G. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon. Ann Rheum Dis 1991;50:359-61.
7. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous Iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
8. Scorza R, Caronni M, Mascagni B et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001;19:503-8.
9. Veale DJ, Muir AH, Morley KD, Belch JJF. Treatment of vasculitic leg ulcers in connective tissue disease with Iloprost. Clin Rheumatol 1995;14:187-91.
10. Zahavi J, Charach G, Schafer R, Toeg A, Zahavi M. Ischaemic necrotic toes associated with antiphospholipid syndrome and treated with iloprost. Lancet 1993;342:862.
11. Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic property and therapeutical potential in peripheral vascular disease, myocardial ischemia and exttacorporeal circulation procedures. Drugs 1992;43:889-924.
12. Belch JJF, Sanibadi A, Dickson R, Sturrock RD, Forbes CD. Effects of Iloprost on white cell behavior. In: Gryglewski RJ, Stock G, eds. Prostacyclin and its stable analogue Iloprost. Berlin: Springer Verlag, 1986:97-102.
13. Stratton R, Shiwen X, Martini G et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108: 241-50.
14. Lamprecht P, Schnabel A, Gross WL. Efficacy of Alprostadil and Iloprost in digital necrosis due to secondary Raynaud's phenomenon. Br J Rheumatol 1998;37:703-4.
15. Kyle MV, Belcher G, Hazleman BL. Placebo controlled study showing therapeutic benefit of Iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992;19:1403-6.
16. Zachariae H, Halkier-Sørensen L, Bjerring P, Heickendorff L. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous Iloprost in systemic sclerosis. Acta Dermatol Venereol 1996;76:236-8.
17. Machherndl S, Kneussl M, Baumgartner H et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J 2001;17:8-13.
18. Rimensberger PC, Spahr-Schopfer I, Berner M et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001;103: 544-8.
19. Zulian F, Costantini C, Montesco MC, Schiavon F, Zacchello F. Successful treatment of gangrene in systemic necrotizing vasculitis with iloprost. Br J Rheumatol 1998;37:228-30.